Tacrolimus as Intervention in the Treatment of Hyperlipidemia after Liver Transplant
Authors:
- André RoyARAndré Roy
- Norman KnetemanNKNorman Kneteman
- Leslie LillyLLLeslie Lilly
- Paul MarottaPMPaul Marotta
- Kevork PeltekianKPKevork Peltekian
- Charles ScudamoreCSCharles Scudamore
- Jean TchervenkovJTJean Tchervenkov
- 27 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (4) , 494-500
Abstract
To measure the effect on serum lipids and other risk factors for cardiovascular disease, we converted the primary immunosuppression of dyslipidemic stable liver transplant recipients from cyclosporine A to tacrolimus. Patients underwent a four-month dietary stabilization period (American Heart Association Step II diet) and serum lipid samples were collected for analysis at a central laboratory. After conversion, dietary counseling and lipid analyses were performed over a six-month postconversion observation period. Enrollment was terminated prematurely due to low patient recruitment rates. Thirteen patients were enrolled and provided postconversion data showing surprisingly strong results. At six months postconversion, total cholesterol (C) was reduced by a mean of 0.61 mmol/L (P=0.017), high density lipoprotein cholesterol (HDL-C) remained unchanged; the mean total C:HDL-C ratio was reduced by 0.87 (P=0.001). Low density lipoprotein cholesterol (LDL-C) reductions were not statistically significant, but we observed a significant and persistent decrease in apolipoprotein B (-0.15 g/L six months postconversion, P=0.031). No changes in homocysteine or in vitamins B6 and B12 were discerned, but although red cell folate remained stable, serum folate increased after conversion. We observed no rejection episodes or any other clinically notable events following conversion. In this study, conversion from cyclosporine to tacrolimus provided a safe and well-tolerated alternative that reduced hyperlipidemia and other recognized cardiovascular risk factors.Keywords
This publication has 24 references indexed in Scilit:
- Cyclosporine A-Induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantationLiver Transplantation, 2004
- Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS)Circulation, 2003
- Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipientsLiver Transplantation, 2001
- Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination surveyAmerican Heart Journal, 2000
- Homocysteine and Cardiovascular DiseaseAnnual Review of Medicine, 1998
- HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATIONTransplantation, 1997
- Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)Liver Transplantation and Surgery, 1997
- HYPERLIPIDEMIA AFTER LIVER TRANSPLANTATIONTransplantation, 1996
- HYPERHOMOCYSTEINEMIA IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS1Transplantation, 1996
- SERUM LIPID CHANGES IN LIVER TRANSPLANT RECIPIENTS IN A PROSPECTIVE TRIAL OF CYCLOSPORINE VERSUS FK506Transplantation, 1994